Hinske Ludwig Christian, Heyn Jens, Hübner Max, Rink Jessica, Hirschberger Simon, Kreth Simone
Department of Anesthesiology, University Hospital of the Ludwig-Maximilians-University Munich, Marchioninistraße 15, D-81377 Munich, Germany.
Department of Anesthesiology, University Hospital of the Ludwig-Maximilians-University Munich, Marchioninistraße 15, D-81377 Munich, Germany; Walter-Brendel Center of Experimental Medicine, Ludwig-Maximilians-University Munich, Marchioninistraße 15, D-81377 Munich, Germany.
Biochem Biophys Res Commun. 2017 Aug 5;489(4):477-483. doi: 10.1016/j.bbrc.2017.05.175. Epub 2017 May 30.
MicroRNAs have established their role as important regulators of the epigenome. A considerable number of human miRNA genes are found in intronic regions of protein-coding host genes, in many cases adopting their regulatory circuitry. However, emerging evidence foreshadows an unprecedented importance for this relationship: Intronic miRNAs may protect the cell from overactivation of the respective host pathway, a setting that may trigger tumor development. AKT2 is a well-known proto-oncogene central to the PI3K/AKT pathway. This pathway is known to promote tumor growth and survival, especially in glioblastoma. Its intronic miRNA, hsa-miR-641, is scarcely investigated, however. We hypothesized that miR-641 regulates its host AKT2 and that this regulation may become dysfunctional in glioblastoma. We found that indeed miR-641 expression differs significantly between GBM tissue and normal brain samples, and that transfection of glioma cells with miR-641 antagonizes the PI3K/AKT pathway. Combining clinical samples, cell cultures, and biomolecular methods, we could show that miR-641 doesn't affect AKT2's expression levels, but down-regulates kinases that are necessary for AKT2-activation, thereby affecting its functional state. We also identified NFAT5 as a miR-641 regulated central factor to trigger the expression of these kinases and subsequently activate AKT2. In summary, our study is the first that draws a connecting line between the proto-oncogene AKT2 and its intronic miRNA miR-641 with implication for glioblastoma development.
微小RNA已确立其作为表观基因组重要调节因子的作用。相当数量的人类微小RNA基因存在于蛋白质编码宿主基因的内含子区域,在许多情况下采用其调控回路。然而,新出现的证据预示着这种关系具有前所未有的重要性:内含子微小RNA可能保护细胞免受相应宿主通路的过度激活,而这种情况可能引发肿瘤发展。AKT2是PI3K/AKT通路中一个众所周知的原癌基因。已知该通路可促进肿瘤生长和存活,尤其是在胶质母细胞瘤中。然而,其内含子微小RNA hsa-miR-641的研究却很少。我们假设miR-641调节其宿主AKT2,并且这种调节在胶质母细胞瘤中可能会功能失调。我们发现,实际上GBM组织和正常脑样本之间miR-641的表达存在显著差异,并且用miR-641转染胶质瘤细胞可拮抗PI3K/AKT通路。结合临床样本、细胞培养和生物分子方法,我们可以证明miR-641不会影响AKT2的表达水平,但会下调AKT2激活所必需的激酶,从而影响其功能状态。我们还确定NFAT5是miR-641调节的触发这些激酶表达并随后激活AKT2的核心因子。总之,我们的研究首次在原癌基因AKT2与其内含子微小RNA miR-641之间建立了联系,这对胶质母细胞瘤的发展具有重要意义。